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Highlights 
We investigated the effect of two inodilators in infants post cardiac surgery. 
 
The effect of levosimendan and milrinone on myocardial function was compared.  
 
We used conventional and two-dimensional speckle tracking strain 
echocardiography. 
 
Biventricular strain demonstrated deterioration initially and improvement later. 
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Objective: We aimed to determine the differential effects of intra-operative 
administration of milrinone versus levosimendan on myocardial function after 
pediatric cardiac surgery. Transthoracic echocardiography was employed for 
myocardial function evaluation, utilizing biventricular longitudinal strain with two-
dimensional speckle tracking echocardiography in addition to conventional 
echocardiographic variables.  
Design: A secondary analysis of a randomized, prospective, double-blinded clinical 
drug trial 
Setting: Two pediatric tertiary university hospitals 
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Participants: Infants between 1-12 months of age diagnosed with ventricular septal 
defect, complete atrioventricular septal defect, or tetralogy of Fallot who were 
scheduled for corrective surgery with cardiopulmonary bypass. 
Interventions: The patients were randomized to receive an infusion of milrinone or 
levosimendan at the start of cardiopulmonary bypass and for 26 consecutive hours. 
Measurements and main results: Biventricular longitudinal strain and conventional 
echocardiographic variables were measured preoperatively, on the first postoperative 
morning and prior to hospital discharge. The association between perioperative 
parameters and postoperative myocardial function was also investigated. Images 
were analyzed for left ventricular (n=67) and right ventricular (n=44) function. The day 
after surgery, left ventricular longitudinal strain was deteriorated in both the milrinone 
and levosimendan groups; 33% and 39%, respectively. The difference was not 
significant. The corresponding deterioration in right ventricular longitudinal strain was 
42% and 50% (non-significant difference). For both groups, biventricular longitudinal 
strain approached their preoperative values at hospital discharge. Preoperative N-
terminal pro-brain natriuretic peptide could predict the left ventricular strain on 
postoperative day one (p=0.014). 
Conclusions: Levosimendan was comparable to milrinone for left and right 
ventricular inotropic support in pediatric cardiac surgery.  
 
Keywords 
Speckle tracking, longitudinal strain, congenital heart defect, cardiopulmonary 
bypass, randomized clinical trial, infant, milrinone, levosimendan 
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Introduction 
Inodilators are widely used to reduce the risk of low cardiac output syndrome (LCOS) 
after cardiac surgery with cardiopulmonary bypass (CPB) in children. In this setting, 
milrinone is the drug of choice 1. Levosimendan is also being used for preventing or 
treating LCOS after pediatric surgery in children 2. It has been demonstrated that 
levosimendan is safe and at least as effective as milrinone in maintaining cardiac 
output in the pediatric post cardiac surgery setting 3-5. To our knowledge, no studies 
are comparing the effect of these two inodilators on myocardial function in children 
assessed by longitudinal strain (LS) using two-dimensional speckle tracking 
echocardiography (2D STE). STE is a relatively new method, which is increasingly 
used to detect left ventricular (LV) and right ventricular (RV) dysfunction. STE 
measures the relative movement of myocardial gray-scale alterations (speckle 
patterns) and can thereby quantify regional and global systolic deformation, strain, 
describing percentage changes in myocardial segment length. It is dimensionless 
and angle-independent with good feasibility and reproducibility. In the longitudinal 
axis of the heart, the myocardium shortens during the contraction in systole, hence 
the negative value of strain (percentage shortening compared to diastole) 
demonstrates the myocardial function. Strain measured along the longitudinal axis is 
the most widely used and best-evaluated method 6,7. The recently published pediatric 
reference values for LV longitudinal strain (GE Medical Systems), shows -17.5% to 
be the cut off for normal 8. LS has been demonstrated to be more sensitive to detect 
changes in myocardial function than traditional echocardiography parameters 9. 
Furthermore, it has a good correlation with LV ejection fraction (EF) measured with 
magnetic resonance imaging 6. Earlier studies have demonstrated that LS is 
significantly impaired on a postoperative day one (POD-1) after cardiac surgery in 
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children and that it has not completely recovered at discharge from the hospital 
compared to the preoperative values 7,10.  
In the present study, we investigated the potentially differential effect of 
levosimendan and milrinone on biventricular LS in the early postoperative period in 
infants undergoing corrective cardiac surgery and tested the null hypothesis that 
these two inodilators exert comparable effects on LV and RV systolic function.  
 
Material and methods 
Study design and patients 
The current study was a secondary analysis of a randomized, prospective, double-
blinded clinical drug trial called MiLe-1. The primary objective in MiLe-1 was to 
investigate the differential effects of milrinone and levosimendan on the incidence of 
acute kidney injury post-pediatric cardiac surgery. The details of MiLe-1 have been 
described elsewhere 11. Briefly, we included seventy-two infants aged one to 12 
months and with three different congenital heart defect diagnoses, who were 
scheduled for elective corrective open-heart surgery with CPB. The patient diagnoses 
were non-restrictive ventricular septal defect (VSD), complete atrioventricular septal 
defect (AVSD) with non-restrictive VSD, and balanced ventricles, and Tetralogy of 
Fallot (ToF). The patients were recruited from October 2014 until April 2017 in two 
centers of congenital cardiac surgery (Sweden and Finland). A written informed 
consent was obtained from the parents prior to the surgery. The study was approved 
by the Swedish Medical Agency and the Regional Ethics Committees in both 
countries. Exclusion criteria included lack of written informed consent from parents, 
previous open-heart surgery, ongoing infection, renal disease, use of nephrotoxic 
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drugs or contrast agents within 24 hours prior to surgery, prematurity, preoperative 
need for mechanical ventilation and/or vasoactive drugs and/or extra corporeal 
membrane oxygenation. The medical staff and the cardiologist who analyzed the 
echocardiography images were blinded to the study drug. The patients were 
randomized to receive either milrinone or levosimendan. The drug infusion was 
initiated in the operating room immediately after the start of the CPB with a loading 
dose of 12 µg/kg of levosimendan or 48 µg/kg of milrinone, followed by a 
corresponding infusion of 0.1 µg/kg/min of levosimendan or 0.4 µg/kg/min of 
milrinone. The protocol allowed the anesthetist in charge to administer an extra bolus 
dose (half the loading dose) at weaning of CPB if the myocardial function was 
reduced on the routine transesophageal echocardiogram performed after weaning 
from CPB. The infusion rate could also be increased up to 0.16 µg/kg/min 
levosimendan or 0.67 µg/kg/min milrinone at any time after CPB-weaning until the 
drug infusion was stopped. The drug was infused for 24 hours, followed by a weaning 
period of two hours, where the infusion rate was reduced to 50% and thereafter it 
was stopped. Should the patient need further inotropic therapy after weaning, 
milrinone infusion was started.  
There was a standardized operating procedure regarding the surveillance and 
treatment of the hemodynamic status with pre-defined target values. The target mean 
arterial pressure (MAP) during and after CPB was 30 mmHg and 45 mmHg, 
respectively. The target levels of serum hemoglobin, serum lactate and ionized 
calcium in serum were:  >100 g/L, < 2 mmol/L and >1.2 mmol/L respectively. 
Hemodynamic data were documented at the following time points: immediately after 
CPB-weaning (0 hours), at 2, 6, 12, 24 hours after CPB, and at the time of the 
echocardiography on the first postoperative morning (POD-1). The age-based Ross 
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classification for heart failure in children 12 was used to grade the preoperative heart 
failure in the patients. The Comprehensive Aristotle score 13 and the risk adjustment 
for congenital heart surgery (RACHS-1) score 14 were used as risk assessment tools. 
Inotropic score (IS) was calculated according to Wernovsky with a slight modification 
15. We added norepinephrine to the formula in line with Gaies’s vasoactive inotropic 
score 16. 
Echocardiography 
The echocardiographic images (Epiq 7, Philips, Andover, AM, USA and Vivid E95, 
General Electric, Horten, Norway) were recorded preoperatively, on the morning of 
POD-1 (whilst ongoing study drug infusion) and prior to the discharge from hospital. 
STE strain measurements, as well as automated 2D EF for LV and fractional area 
change for RV (RV-FAC) were analyzed from the apical 4-chamber view. The STE 
strain analyses were performed by one senior pediatric cardiologist (TO), using the 
VVI program (Syngo USWP 3.0, Siemens Healthineers, Erlangen, Germany) as 
earlier described 17,18. Manual tracing of LV endocardial surface was performed in a 
single still frame in mid-systole. Tracing began at the septal edge of the mitral valve 
annulus, extended to the apex and returned to the lateral edge of the mitral valve 
annulus. In the case of RV, the manual tracing of the endocardial surface began at 
the edge of the tricuspid valve annulus, extended to the apex of the ventricle without 
incorporation of the papillary muscle complex, and returned basally to the septal 
edge of the tricuspid valve annulus. Velocity vectors were then automatically 
calculated for each frame of the cardiac cycle by the VVI algorithm. Tracings were 
accepted only when the endocardial border was correctly followed throughout the 
entire cardiac cycle. Individual regions of the border were adjusted until the border 
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was correctly tracked for each frame when necessary. The ventricular septal defect 
area or postoperatively the patch area were rejected from the analysis.  
Statistical analysis 
A power calculation was performed for the postoperative incidence of acute kidney 
injury in MiLe-1 11. In order to evaluate the sample size for the current sub-study, we 
performed a post-hoc power calculation based on the absolute values of LV-LS on 
POD-1, the primary end-point, in the whole study sample. We found that in order to 
detect a 30% difference in LV-LS on POD-1 between the two study groups, with a 
power of 80% and a level of significance of 0.05 and at a standard deviation of 4.1, 
we would need 19 patients in each group, and for a difference of 25% we would need 
27 patients in each group.  
For comparison between groups, Fisher’s Exact test was used for dichotomous 
variables, Chi square test for non-ordered categorical variables, and Mann-Whitney 
U-test for continuous variables. We used mixed-model repeated measurements to 
investigate differences between and within the groups over time (group versus time 
interaction) assuming unstructured covariance pattern. Linear regression analyses 
were performed to relate LV-LS on POD-1 to the following independent variables: 
congenital heart lesion, age, preoperative NT-Pro-BNP, center, study drug, age-
based Ross classification, the Comprehensive Aristotle score, and CPB-time. For 
evaluation of statistical significance, we chose p-values lower than 0.05. The data 
were analyzed using SAS v9.4 (Cary, NC) and IBM SPSS statistics for Windows, 
Version 25.0 (Armonk, NY). Figures were created in GraphPad Prism 8.0.0 for 
Windows, San Diego, California, USA. 
 




The study Consort flow chart is illustrated in Figure 1. There were no significant 
differences in the demographic data between the treatment groups (Table 1). 
Regarding the study drug, only one patient in the levosimendan group and two 
patients in the milrinone group received an extra bolus of study drug during CPB 
weaning. The infusion rate of the study drug was increased in two patients in each 
group. Concerning the vasoactive agents, none of the patients received dopamine, 
dobutamine or vasopressin, consequently the calculation of the inotropic score was 
based on norepinephrine and epinephrine.  
The echocardiographic examination prior to hospital discharge was performed on day 
7 (5;8) (median IQR) in the milrinone group and on day 7 (6;11) in the levosimendan 
group. 
Hemodynamics and clinical outcome variables 
Hemodynamic variables are depicted in Figures 2a and 2b. Early after weaning from 
CPB, heart rate and mean arterial pressure increased, while central venous pressure 
decreased. Central venous saturation and serum lactate decreased, while inotropic 
score remained largely constant. These patterns were similar for both groups. In fact, 
there were no significant differences in the hemodynamic variables between the 
groups over time (Figure 2a and 2b), or at the time of echocardiographic examination 
on the POD-1 (data not shown). Additionally, there were no significant differences 
between the groups regarding the clinical outcome, in terms of time on the ventilator, 
hospital stay or mortality, and adverse advents, as demonstrated in Table 2.  
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Echocardiographic analyses 
Biventricular LS in the study groups are demonstrated in Figure 3, and all 
echocardiographic variables are shown in Table 3. Cardiac surgery induced a 
significant deterioration in LV-LS (less negative LS), measured at POD-1, compared 
to the preoperative value both in the milrinone group (33% deterioration, p<0.0001) 
and in the levosimendan group (39% deterioration, p<0.0001). At hospital discharge, 
LV-LS had partially recovered to the preoperative level in both groups.  
When compared over time, there was a significant difference between the two groups 
(p=0.020), probably reflecting slightly different patterns of changes in LV-LS. In post-
hoc analyses of the three different measurement time points, LV-LS did not differ 
significantly between the treatment groups (preoperative, POD-1 and prior to 
discharge from hospital [p=0.57, 0.12 and 0.14 respectively]). Thus, although not 
significant, there was a trend for more impaired LV-LS in the levosimendan group 
compared to the milrinone group on POD-1 and, vice versa, at discharge from the 
hospital there was a trend for more impaired LV-LS in the milrinone group. 
RV-LS also decreased on POD-1, compared to the preoperative value both in the 
milrinone group (42% deterioration, p<0.0001) and in the levosimendan group (50% 
deterioration, p<0.0001) with only partial recovery at hospital discharge in both 
groups. Postoperative changes in RV-LS, LVEF, and RV-FAC did not differ between 
the groups over time. There was a trend for a lower LVEF on POD-1 in the 
levosimendan group (31% vs. 36%, p=0.065), with no difference at hospital 
discharge.  
When the biventricular LS measurements in the whole study population were divided 
by the type of cardiac lesion, the changes in strain measurements over time looked 
quite similar (Figure 4), except for the low preoperative value of RV-LS in the patients 
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with VSD. In fact, there was no significant difference between the type of heart 
defects over time for LV-LS and RV-LS (p = 0.84 and 0.16 respectively) and LV-EF 
and RV-FAC (p = 0.94 and 0.97 respectively).   
Linear regression model demonstrated a significant relationship between 
preoperative NTproBNP and LV-LS on POD-1 (p = 0.014 and beta-score 0.9 with 
95% CI 0.2;1.6), while other variables were not associated with LV-LS on POD-1. 
Additional information on the parameters in supplementary data as supplementary 




In the present study, we evaluated the potentially differential effect of levosimendan 
and milrinone on biventricular systolic function, assessed by strain echocardiography, 
early after pediatric cardiac surgery. The main finding was that there were no 
significant differences between the groups with respect to early (POD-1) or late 
(hospital discharge) LV-LS or RV-LS. Furthermore, none of the inodilators could 
prevent a substantial fall in LV-LS (30-40%) or RV-LS (40-50%) the day after surgery. 
In addition, biventricular LS was only partially restored at the time of hospital 
discharge. Finally, there was a significant correlation between preoperative 
NTproBNP and LV-LS on POD-1. 
To our knowledge, this is the first study which evaluates and compares the effects of 
two inotropic agents on LV and RV systolic function by the use of 2D STE in pediatric 
cardiac surgery. In a blinded randomized clinical trial, Pellicer et al, compared the 
effect of levosimendan and milrinone on 20 neonates undergoing open heart surgery. 
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They reported the number of patients having EF < 55% and fractional shortening 
(FS) < 28% on the POD-1 and found no significant difference between the two 
groups 3. Lechner et al compared the effects of levosimendan and milrinone on FS 
and on the cardiac index (measured with transesophageal Doppler technique) in 40 
infants after cardiac surgery. They found no significant difference in postoperative FS 
measured up to 48 hours after CPB, or in the cardiac index between the two groups. 
However, the patients in the levosimendan group had an increase in cardiac index 
over time while it remained stable over time in the milrinone group 4. In neither of 
these studies was a bolus dose of the inotropic agent administered during CPB.  
In a recent blinded randomized study on 31 adult patients with normal preoperative 
myocardial function undergoing aortic valve replacement for aortic stenosis, 
Fredholm et al 19 compared the effect of levosimendan and milrinone on early 
postoperative LV-LS. The study drug infusion was initiated after arrival to the ICU, 
and the strain measurements were performed during three hours while the inotrope 
was administered in a step-up fashion. During this period preload, afterload and heart 
rate were maintained constant. Both drugs induced a dose-dependent improvement 
in LV-LS and cardiac index, but there was no significant difference between the effect 
of these two inodilators on either LV-LS or cardiac index. Our study confirms the 
results of these prior studies that levosimendan and milrinone exert comparable LV 
inotropic effects in the early postoperative period after cardiac surgery.  
In our study, several new aspects provide valuable information regarding the effect of 
these two inotropes on the myocardial function in this young patient group 
undergoing cardiac surgery. Firstly, our study is to our knowledge the first 
randomised study in patients with ToF, VSD, and AVSD, aged one to 12 months, 
investigating cardiac function in connection with a perioperative infusion of milrinone 
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or levosimendan. Secondly, we used STE and strain, a relatively new technique in 
echocardiography, which is more sensitive to detect changes in myocardial function 
than traditional echocardiography parameters 9. Thirdly, we examined biventricular 
function, and lastly, we gave a loading dose of the inotropic agent at the initiation of 
CPB aiming for obtaining an early effect of the drug. In our units, it is routine practice 
to initiate the inotropic infusion around the time of CPB initiation, with or without 
loading dose, with the purpose of reducing the risk of LCOS. 
The pattern of reduction of myocardial function early after cardiac surgery with partial 
restoration of function during the stay in hospital was similar to what has been 
reported earlier 20.  
In the present study, preoperative NTproBNP predicted worse LV-LS on POD-1. 
Although Carmona et al found a correlation between preoperative NTproBNP and 
clinical parameters of LCOS 21, the association between preoperative NTproBNP on 
LV-LS after cardiac surgery in children has, to our knowledge, not been studied 
earlier. The correlation of age, age-based Ross classification, the Comprehensive 
Aristotle score, and CPB-time with LV-LS on POD-1 in our study were weak. This 
was probably due to the fairly homogenous study population. Perdreau et al found a 
correlation between aortic cross-clamp time (ACC) > 30 minutes and worse 
postoperative LV-LS 7. De Boer et al investigated postoperative LS, in a more 
heterogenous pediatric population, compared with our study, and found a correlation 
between CPB- and ACC-time with RV-LS but not LV-LS 10.  
There was no association between the type of heart defect and LV-LS post-
operatively. This was despite the fact that the hemodynamics in VSD, AVSD, and 
ToF result in different types of load on the left ventricle. In our patient population, 
there was a variation in LV-LS pre-operatively, and patients with more affected 
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preoperative LV-LS seemed to exhibit worse LV function in terms of LV-LS on POD-
1. However, the variation in pre-operative LV-LS was not due to a systematic 
variation between patients with different heart defects, but rather a variation across 
the entire cohort.  
Our study has several limitations. The patient population was restricted to merely 
three diagnoses with an age span of one to 12 months, which makes it difficult to 
generalize the results to more complex diagnoses and other age groups. Another 
limitation was the lack of a placebo group. However, in our centers, milrinone is used 
routinely to reduce the risk of LCOS postoperatively, and in this setting, including a 
placebo group and withholding patients from active treatment would have been 
ethically unjustified. Finally, there was some missing data on right ventricular function 
due to the fact that the evaluations of RV-LS is technically more challenging 
compared with the LV-LS 22, especially on POD-1 when the acoustic window often is 
poor.  
The strengths of this study were the following: firstly, it was a double-blinded 
randomized clinical trial, performed in two centers. Secondly, the responsible 
physicians followed a study protocol to maintain the hemodynamic status of the 
patients as similar as possible. In fact, there were no significant differences between 
the study groups over time regarding hemodynamic variables. Thirdly, all the strain 
analyses were performed merely by a single cardiologist blinded to the study groups. 
Fourthly, to have a fairly homogenous study population, we only included patients 
aged one to 12 months, with VSD, AVSD, or ToF undergoing corrective surgery.  
In conclusion, there were no significant differences between the groups with respect 
to early or late LV or RV systolic function assessed by STE after corrective heart 
surgery for ToF, AVSD, or VSD.   
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Figure Legends 
Figure 1. Study CONSORT flow chart. Further details regarding the inclusion and 





Figure 2 Hemodynamics over time in the two study groups; a) heart rate, mean 
arterial pressurea and central venous pressure, and b) central venous saturationa, 
serum lactatea, and inotropic scorea. Filled rhomboids represent levosimendan, non-
filled rhomboids milrinone. Horizontal axes show hours after CPB-weaning and vertical 
axes measurement units. Data are shown as mean with 95% confidence interval. 
There were no significant differences between groups over time in any of the variables. 
a Data previously reported in reference 11. 






         
 19 
Figure 3. Left and right longitudinal strain (LV-LS and RV-LS) in the two study 
groups. Longitudinal strain represents the shortening of the myocardium in systole 
compared to diastole in the longitudinal plane, hence the unit of negative percent on 
the y-axis. Data are shown as mean values with 95% confidence interval. Filled 
rhomboids resemble the levosimendan group, empty rhomboids the milrinone group. 
The three time points of the strain measurements were preoperative, on the first 
postoperative morning (POD-1), and at discharge from the hospital. LV-LS and RV-
LS were impaired in both groups on POD-1 compared to the preoperative values, 
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Figure 4. Left and right longitudinal strain (LV-LS and RV-LS) in the whole study 
population differentiated by the type of congenital heart defect. Longitudinal strain 
represents the shortening of the myocardium in systole compared to diastole in the 
longitudinal plane, hence the unit of negative percent on the y-axis. Data are shown 
as mean values with 95% confidence interval. Empty circles resemble VSD, filled 
circles AVSD, and filled triangles ToF. The three time points of the strain 
measurements were preoperative, on the first postoperative morning (POD-1), and at 
discharge from the hospital. The changes in strain over time were quite similar for 
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Table 1: Patient demographic and perioperative data 
 Levosimendan (n = 32) Milrinone (n = 38) 
Age at operation (months) 5.9 (2.9) 5.6 (2.7) 
Gestational age (weeks) 38.4 (2.3) 38.6 (2.2) 
Preoperative weight (kg) 6.4 (2.0) 6.2 (1.5) 
Male 16 (50.0%) 18 (47.4%) 
Female 16 (50.0%) 20 (52.6%) 
Non-restrictive VSD 13 (40.6%) 14 (36.8%) 
Complete AVSD 7 (21.9%) 8 (21.1%) 
Tetralogy of Fallot 12 (37.5%) 16 (42.1%) 
Preoperative fractional shortening (%) 36.4 (6.3) 39.2 (6.8) 
Preoperative serum NT-proBNP (ng/L) 2622 (6276) 2474 (4539) 
CPB-duration (minutes)  90 (33) 93 (45) 
ACC-duration (minutes)  61 (23) 62 (33) 
Lowest temperature during CPB (°C) 33.7 (1.8) 33.7 (1.4) 
Age-based Ross classification  4.8 (3.4) 4.7 (3.4) 
RACHS-1 score 2 25 (78.1%) 30 (78.9%) 
RACHS-1 score 3 7 (21.9%) 8 (21.1%) 
Comprehensive Aristotle score  9.0 (2.6) 8.3 (2.0) 
Values are mean +SD or numbers, n (%).  Data in this table have been previously reported11. There 
were no significant differences among the variables. ACC = aortic cross-clamp time; AVSD = complete 
atrioventricular septal defect;  CPB = cardiopulmonary bypass; NT-proBNP = N-terminal pro-brain 
natriuretic peptide; RACHS-1 = risk adjustment for congenital heart surgery; VSD = non-restrictive 
ventricular septal defect. 
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Table 2: Clinical Outcome and Adverse Events 
 Levosimendan n = 32 Milrinone n = 38 P value 
Hemodynamic support (POD-1) 
Active external 
atrioventricular-pacing 
4 (12.5%) 2 (5.3%) 0.40 
Antiarrhythmic agents 
Amiodarone  4 (12.5%) 3 (8.1%) 0.83 
Betablocker  1 (3.1%) 0 (0%) 0.93 
Others  0 (0%) 0 (0%) 1.00 
Nitric oxide  4 (12.5%) 2 (5.3%) 0.54 
Norepinephrine and/or 
epinephrine 
15 (46.9%) 22 (57.9%) 0.47 
Inotropic score  0 (0;10.5) 3 (0;8) 0.59 
Adverse events a 
Junctional ectopic 
tachycardia  
3 (9.4%) 3 (7.9%) 1.00 
Atrioventricular block 
III  
2 (6.3%) 0 (0.0%) 0.21 
Sinus tachycardia 
(>180/min)  
0 (0.0%) 0 (0.0%) 1.00 
Other outcome parameters a 
Length of ventilator 
support (hours)  
30.0 (15.5; 54.5) 21.0 (10.0; 32.5) 0.21 
PICU stay (days)  3.0 (2.0; 5.5) 2.0 (2.0; 3.0) 0.06 
Hospital stay (days)  9.5 (8.0; 14.5) 8.0 (7.0; 11.0) 0.10 
28-day mortality  0 (0.0%) 0 (0.0%) 1.00 
Data are shown as numbers, n (%) or median (interquartile range). a values previously reported in ref 
11.  
POD-1 = first postoperative morning; PICU = pediatric intensive care unit. 
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Table 3: Echocardiographic parameters 
LV-LS (%) LVEF (%) 


















-19.2 (5.5) -19.8 
(3.3) 
 0.57  52 (7) 51 (9) 0.77  
POD-1 -11.8 (4.6) -13.2 
(3.6) 
 0.12  31 (11) 36 (7) 0.065  
At 
discharge 
-17.3 (3.3) -15.7 
(3.8) 









0.051 < 0.0001    0.0002 < 0.0001   




















-20.1 (6.6) -20.1 
(5.9) 
0.96   30 (9) 28 (8) 0.49  
POD-1 -10.1 (4.3) -11.6 
(3.4) 
0.23   23 (11) 27 (8) 0.13  
At 
discharge 
-13.3 (3.5) -13.7 
(3.1) 









< 0.0001 < 0.0001    0.77 0.59   
 
Note: Values are mean (standard deviation) 
Abbreviations: EF = ejection fraction; FAC = fractional area change; LS = longitudinal strain, LV = left ventricle; 
PInteraction = P value between groups over time; Preop = preoperative; POD-1 = postoperative day one;  
RV = right ventricle 
         
